Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China ...Middle East

Study participants receiving 0.6 and 1.2 mg ecnoglutide once weekly for 24 weeks achieved HbA1c reductions of 1.96 and 2.43% from baseline, respectively, compared to 0.87 % for placebo In the 1.2 mg ecnoglutide cohort, 76.1% of participants achieved HbA1c ≤ 6.5% and 35.2% achieved HbA1c

Hence then, the article about sciwind biosciences announces positive topline results from phase 3 clinical trial of ecnoglutide xw003 a long acting camp signaling biased glp 1 analog in adult patients with type 2 diabetes in china was published today ( Wednesday 03/01/2024 - 05:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sciwind Biosciences Announces Positive Topline Results from Phase 3 Clinical Trial of Ecnoglutide (XW003), a Long-acting cAMP Signaling Biased GLP-1 Analog, in Adult Patients with Type 2 Diabetes in China )

Also on site :

• Police respond to incident at property in Dudley as residents 'spot armed police' in street
• Sinkhole on East Franklin Street Closes Lanes; Chapel Hill Urges for Detours
• Fire crews and Hazmat teams responded to fire involving lithium ion batteries at Higuera Street facility